Medical Technology Breaking News: Aethlon Medical (OTCBB:
AEMD) Announces Presentation of Ebola Treatment Data This Friday, November 14th
at the ASN Annual Meeting
SAN DIEGO - November 10, 2014 (Investorideas.com newswire)
Aethlon Medical, Inc. (OTCBB:AEMD),
the pioneer in developing targeted therapeutic devices to address infectious
disease and cancer, announced today that treatment data resulting from the
administration of Hemopurifier® therapy to a patient infected with Ebola virus
will be presented this Friday, November 14th at the American Society of
Nephrology (ASN) Annual Meeting.
The
treatment data will be presented during an ASN Special Session on Ebola and
Dialysis by Professor Helmut Geiger M.D., Chief of Nephrology at Goethe
University, Frankfurt University Hospital, where the patient was treated. The
data will include the results of patient viral load measurements taken before
and after Hemopurifier® administration.
Additionally,
the quantification of ebola viruses captured within the Hemopurifier® during
treatment will be reported. On November 5th, officials at Frankfurt University
Hospital disclosed that the treated patient, who was suffering from multiple
organ failure, was no longer infected with ebola virus and is expected to make
a full recovery.
The
ASN Annual Meeting is the world's premier nephrology conference with more than
13,000 medical professionals from across the globe attending this years
gathering at the Pennsylvania Convention Center in Philadelphia.
The
Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets
the rapid elimination of viruses and immunosuppressive proteins from the
circulatory system of infected individuals. At present, no antiviral therapy or
vaccine has proven to be effective against Ebola virus infection in humans.
According to the World Health Organization (WHO), more than 5,000 deaths have
been attributed to the current ebola virus epidemic. The patient at Frankfurt
University Hospital was administered Hemopurifier® therapy through special
approval from The Federal Institute for Drugs and Medical Devices
(Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM), an independent
federal higher authority within the portfolio of the Federal Ministry of Health
of Germany.
In
the care of ebola-infected individuals, the Hemopurifier targets two unmet
medical needs: the rapid elimination of circulating viruses to inhibit
continued progeny virus replication and the direct targeting of secreted
glycoproteins that overwhelm the host immune response. The broad-spectrum
antiviral and immunotherapeutic device is deployed for use within the global
infrastructure of dialysis and CRRT machines already located in hospitals and
clinics.
Aethlon
is also preparing to initiate the first U.S. clinical studies of Hemopurifier
therapy based on the United States Food and Drug Administration's (FDA)
approval of an Investigational Device Exemption (IDE) that was previously
submitted by the Company. The study will contribute safety data to advance the
device as a broad-spectrum countermeasure against pandemic threats, including
ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).
To
date, Hemopurifier therapy has been successfully administered in approximately
one hundred treatment experiences in health compromised HIV and HCV infected
individuals. These studies were conducted at the Apollo Hospital, Fortis
Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all
located in India. In vitro validation studies that demonstrated the ability of
the Hemopurifier to capture Zaire and other strains of ebola virus have been
conducted by researchers at the United States Army Medical Research Institute
for Infectious Diseases (USAMRIID) and the United States Centers for Disease
Control and Prevention (CDC).
In
vitro studies conducted by leading government and non-government research
organizations have also validated that the Hemopurifier® captures a
broad-spectrum of bioterror and pandemic threats. Like ebola virus, many of
these threats are not addressed with an effective drug or vaccine. Viruses
validated to be captured by the Hemopurifier® include; dengue hemorrhagic
virus, lassa hemorrhagic virus, H5N1 avian influenza (bird flu), the
reconstructed 1918 influenza virus (r1918), 2009 H1N1 influenza virus (swine
flu), West Nile virus, and monkeypox, which serves as a model for human
smallpox infection.
In
oncology, the Hemopurifier® has been validated to capture tumor-secreted
exosomes, which suppress the immune response and contribute to the spread of
metastasis in cancer patients. In both oncology and infectious disease
indications, the Hemopurifier® can be combined with standard of care therapies
as an adjunct strategy to improve patient benefit.
About Aethlon Medical, Inc.
Aethlon
Medical creates targeted therapeutic devices to address infectious disease,
cancer and neurodegenerative disorders. The company's lead product is the
Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device
that selectively targets the broad-spectrum elimination of circulating viruses
and tumor-secreted exosomes that promote cancer progression. Exosome Sciences,
Inc. is a majority owned subsidiary that is advancing exosome-based products to
diagnose and monitor cancer, infectious disease and neurological disorders. For
more information, please visit http://www.aethlonmedical.com and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties. Such
forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that the ESI will not be able to commercialize its future
products, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness
to established cancer or hepatitis C therapies or as a standalone cancer or
hepatitis C therapy or as a broad spectrum defense against viral pathogens,
including ebola, the Company's ability to raise capital when needed, the
Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through
outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA
contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances,
actual results could differ materially as a result of a variety of factors,
including the risks associated with the effect of changing economic conditions
and other risk factors detailed in the Company's Securities and Exchange
Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: This email and content is
for subscribers /investors at Investorideas and not for duplication and
publication on other websites or blogs. If you would
like to publish any content sent from investorideas email please send us a
written request. Publication of our email alerts without written
permission will be considered a violation of our copyright. The Investorideas.com
newswire is a third party publisher of news and research as well as creates
original content as a news source. Original content created by investorideas is
protected by copyright laws other than syndication rights. Investorideas is a
news source on Google news and Linkedintoday plus hundreds of syndication
partners. Our site does not make recommendations for purchases or sale of
stocks or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investment involves
risk and possible loss of investment. This site is currently compensated by
featured companies, news submissions, content marketing and online advertising.
Contact each company directly for press release questions. Disclosure is posted
on each release if required but otherwise the news was not compensated for and
is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, mining stocks, oil and gas stocks and more...
Any redistribution or
publishing of information from our newsletter alerts and e-mails without the
written consent of Investorideas.com is strictly forbidden
No comments:
Post a Comment